Live Analyst Rating Changes 35724 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matt Phipps
WB

Matt Phipps

William Blair
Wall Street Analyst
★★★☆☆
#2049
on 13Foresight · ranked by our own returns
50%
Success Rate
-0.3%
Average Return
58 of 117 calls profitable · +18.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 50% of Matt Phipps's ratings turned a profit when each position was held for 1 year — averaging -0.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

202 Buy 57 Hold 0 Sell
Matt's Stock Coverage 41 ratings · 2026-09-30
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
JBIO
Jade Biosciences
 Sep 30, 2026 BUY Strong Buy
+315.2% avg upside
16 analysts
 — · ·
ABBV
AbbVie
 Sep 28, 2026 BUY Strong Buy
-7.7% avg upside
47 analysts
 — -1.1% ·
AUTL
Autolus Therapeutics
 Sep 25, 2026 BUY Strong Buy
+471.1% avg upside
16 analysts
 — +0.0% ·
CGEM
Cullinan Management
 Sep 24, 2026 BUY Strong Buy
+131.3% avg upside
16 analysts
 — -4.1% ·
KYTX
Kyverna Therapeutics, Inc.
 Sep 24, 2026 BUY Strong Buy
+299.4% avg upside
8 analysts
 — -1.4% ·
AMGN
Amgen
 Sep 22, 2026 BUY Buy
-23.6% avg upside
57 analysts
 — +2.5% ·
CMPX
Compass Therapeutics
 Sep 22, 2026 BUY Strong Buy
+584.7% avg upside
20 analysts
 — -11.3% ·
NAMS
NewAmsterdam Pharma Company
 Sep 18, 2026 BUY Strong Buy
+100.5% avg upside
19 analysts
 — +8.1% ·
ZNTL
Zentalis Pharmaceuticals
 Sep 15, 2026 BUY Buy
+401.4% avg upside
20 analysts
 — -13.3% ·
EVMN
Evommune, Inc.
 Sep 09, 2026 HOLD Strong Buy
+208.8% avg upside
13 analysts
 — -22.6% ·
UPB
Upstream Bio, Inc.
 Sep 08, 2026 BUY Strong Buy
+471.5% avg upside
9 analysts
 — -16.2% ·
CLYM
Climb Bio
 Sep 03, 2026 BUY Strong Buy
+90.1% avg upside
20 analysts
 — -18.5% ·
ARGX
Argenx Se
 Sep 02, 2026 BUY Strong Buy
-15.0% avg upside
48 analysts
 — -8.6% ·
TENX
Tenax Therapeutics
 Aug 31, 2026 HOLD Buy
+816.8% avg upside
9 analysts
 — -1.6% ·
INCY
Incyte
 Aug 19, 2026 HOLD Buy
-11.2% avg upside
48 analysts
 — -3.6% ·
BMY
Bristol-Myers Squibb
 Aug 14, 2026 HOLD Buy
-2.5% avg upside
42 analysts
 — -1.5% ·
JANX
Janux Therapeutics Inc
 Aug 13, 2026 BUY Strong Buy
+167.8% avg upside
22 analysts
 — +3.6% ·
ZURA
Zura Bio
 Aug 11, 2026 BUY Strong Buy
+291.1% avg upside
13 analysts
 — -28.1% ·
GMAB
Genmab
 Aug 11, 2026 BUY Strong Buy
+79.2% avg upside
27 analysts
 — +14.6% ·
XNCR
Xencor
 Aug 06, 2026 BUY Strong Buy
+41.4% avg upside
27 analysts
 — +28.0% ·
INSM
Insmed
 Aug 06, 2026 BUY Strong Buy
+48.8% avg upside
37 analysts
 — -11.3% ·
CNTX
Context Therapeutics
 Aug 06, 2026 BUY Strong Buy
+1538.1% avg upside
12 analysts
 — -31.4% ·
IMA
ImageneBio
 Aug 05, 2026 BUY Strong Buy
+290.0% avg upside
13 analysts
 — -19.3% ·
KROS
Keros Therapeutics
 Aug 04, 2026 HOLD Strong Buy
+111.7% avg upside
21 analysts
 — +12.7% ·
JSPR
Jasper Therapeutics
 Jun 01, 2026 HOLD Buy
+4522.4% avg upside
18 analysts
 — +14.0% ·
AXSM
Axsome Therapeutics
 Jan 03, 2026 BUY Strong Buy
+26.8% avg upside
30 analysts
 — +8.0% ·
IONS
Ionis Pharmaceuticals
 Oct 11, 2025 BUY Strong Buy
+64.8% avg upside
43 analysts
$116.76
157.49% Upside
 -37.0% ·
DNTH
Dianthus Therapeutics
 Sep 13, 2025 BUY Strong Buy
+15.1% avg upside
31 analysts
 — +186.7% ·
INKT
MiNK Therapeutics
 Aug 29, 2025 HOLD Strong Buy
+79.5% avg upside
6 analysts
 — -19.8% ·
AGEN
Agenus
 Aug 29, 2025 HOLD Strong Buy
+19.7% avg upside
19 analysts
 — +83.2% ·
VRTX
Vertex Pharmaceuticals
 Jun 28, 2025 BUY Strong Buy
-16.3% avg upside
62 analysts
 — +10.4% ·
MRNA
Moderna
 Jun 07, 2025 HOLD Hold
-47.8% avg upside
38 analysts
 — +68.6% ·
NCNA
Nucana
 Apr 25, 2025 HOLD Buy
+866.8% avg upside
9 analysts
 — · ·
TPST
Tempest Therapeutics
 Apr 25, 2025 HOLD Buy
+2545.2% avg upside
18 analysts
 — -76.9% ·
IMUX
Immunic
 Mar 29, 2025 BUY Strong Buy
+324.0% avg upside
22 analysts
$1.20
86.78% Downside
 +0.0% ·
RNTX
Rein Therapeutics
 Dec 29, 2022 HOLD Strong Buy
+1036.5% avg upside
6 analysts
 — +62.8% ·
PVLA
Palvella Therapeutics
 Jan 03, 2022 BUY Strong Buy
+20.8% avg upside
27 analysts
 — -72.1% ·
ATRA
Atara Biotherapeutics
 Dec 07, 2021 BUY Buy
+118.7% avg upside
18 analysts
 — · ·
ATNM
Actinium Pharmaceuticals
 Nov 19, 2021 BUY Strong Buy
+504.3% avg upside
11 analysts
 — +56.6% ·
BIIB
Biogen
 Jul 23, 2021 BUY Strong Buy
+12.3% avg upside
53 analysts
 — -36.6% ·
NKTR
Nektar Therapeutics
 Jun 11, 2021 BUY Strong Buy
+26.6% avg upside
26 analysts
 — -81.2% ·
🔒 36 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Matt Phipps — Frequently Asked Questions
How accurate are Matt Phipps's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Matt's ratings were profitable over a one-year hold, with an average return of -0.4% per rating, or +18.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Matt ranked on 13Foresight?
Matt Phipps is currently ranked #2049 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matt cover?
Matt most recently has ratings on JBIO, ABBV, AUTL, CGEM, KYTX, AMGN, CMPX, NAMS, ZNTL, EVMN, UPB, CLYM and 29 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.